907972-04-7

Basic information

• Product Name: 2-PYRIDIN-4-YLMETHYL-PIPERAZINE
• Synonyms: 2-PYRIDIN-4-YLMETHYL-PIPERAZINE;2-(4-pyridinylmethyl)Piperazine
• CAS NO: 907972-04-7
• Molecular Formula: C10H15N3
• Molecular Weight: 177.25
• Mol File: 907972-04-7.mol

Chemical Properties

• Boiling Point: 323.026°C at 760 mmHg
• Flash Point: 149.161°C
• Appearance: /
• Density: 1.042g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.528
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-PYRIDIN-4-YLMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PYRIDIN-4-YLMETHYL-PIPERAZINE(907972-04-7)
• EPA Substance Registry System: 2-PYRIDIN-4-YLMETHYL-PIPERAZINE(907972-04-7)

Safety Data

• Hazardous Substances Data: 907972-04-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2-PYRIDIN-4-YLMETHYL-PIPERAZINE is used as a building block for the synthesis of new drug candidates and chemical probes for biological studies due to its diverse biological activities and potential in the treatment of various diseases.
Used in Drug Discovery:
2-PYRIDIN-4-YLMETHYL-PIPERAZINE is used as a promising candidate for further exploration in drug discovery efforts because of its ability to modulate specific biological targets.
Used in the Treatment of Various Diseases:
2-PYRIDIN-4-YLMETHYL-PIPERAZINE is used as a potential treatment for various diseases, including cancer, neurological disorders, and psychiatric conditions, due to its diverse biological activities and potential therapeutic effects.

InChI:InChI=1/C10H15N3/c1-3-11-4-2-9(1)7-10-8-12-5-6-13-10/h1-4,10,12-13H,5-8H2

Upstream product

• 1534361-86-8 3-(pyridin-4-ylmethyl)piperazine-2,5-dione 
• 37535-57-2 (S)-2-((tert-butoxycarbonyl)amino)-3-(pyridin-4-yl)propanoic acid 

Downstream Products

• 1534361-70-0 1,1,1,3,3,3-hexafluoro-2-(4-(2-(4-pyridinylmethyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-2-propanol 

Relevant articles and documents

Small molecule disruptors of the Glucokinase-Glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept

Small molecule activators of glucokinase have shown robust efficacy in both preclinical models and humans. However, overactivation of glucokinase (GK) can cause excessive glucose turnover, leading to hypoglycemia. To circumvent this adverse side effect, we chose to modulate GK activity by targeting the endogenous inhibitor of GK, glucokinase regulatory protein (GKRP). Disrupting the GK-GKRP complex results in an increase in the amount of unbound cytosolic GK without altering the inherent kinetics of the enzyme. Herein we report the identification of compounds that efficiently disrupt the GK-GKRP interaction via a previously unknown binding pocket. Using a structure-based approach, the potency of the initial hit was improved to provide 25 (AMG-1694). When dosed in ZDF rats, 25 showed both a robust pharmacodynamic effect as well as a statistically significant reduction in glucose. Additionally, hypoglycemia was not observed in either the hyperglycemic or normal rats.